CAREN MASON ELECTED TO STAAR'S BOARD OF DIRECTORS ~Stockholders Approve All Proposals at Company Annual Meeting~ MONROVIA, CA

MASON ELECTED TO STAAR'S BOARD OF DIRECTORS

~Stockholders Approve All Proposals at

Company Annual Meeting~

MONROVIA, CA, June 10, 2014 -- STAAR Surgical Company

(NASDAQ: STAA) a leading developer, manufacturer and marketer of implantable lenses and delivery systems for the eye, reported

the results of its Annual Meeting of Stockholders held yesterday. Stockholders approved all proposals at the meeting and reelected

all directors standing for election. In addition, Caren Mason was elected to the board.

Ms. Mason brings a total of more than 35 years of marketing

and executive leadership experience in medical technology and life science companies in a range of large, transitioning and entrepreneurial

environments to STAAR. She was previously the CEO and a director of Verinata Health, a provider of non-invasive prenatal genetic

testing services. Prior, she served as the CEO and a director of Quidel Corporation (QDEL) where she led the successful turnaround

of this diagnostic point-of-care testing company. Ms. Mason has also served as CEO at MiraMedica, Inc. and eMed Technologies, Inc.

Her healthcare industry experience also extends to 22 years of marketing and executive positions with General Electric Healthcare,

Bayer AG, and Baxter/American Hospital Supply.

"We are privileged to have someone

with Caren's deep healthcare background, judgment, and proven marketing and executive leadership skills in guiding strong

companies through accelerated growth periods on our Board," said Mark Logan, Chairman of the Board. "Her expertise

leading public companies will be a significant asset as STAAR continues to accelerate its growth globally. We are confident that

her energy, guidance and leadership will help us further develop and execute our corporate growth strategy."

am delighted to be working with Barry Caldwell, the executive management team and the STAAR board

of directors," said Ms. Mason." The Company has demonstrated its ability to deliver superior refractive technologies

to the worldwide market with the Visian ICL and a robust pipeline is under development to expand that proven platform. I look forward

to being a part of the next stage of its growth as we continue to seek ways to increase value for our shareholders."

In addition to serving on the boards of Verinata, Quidel, MiraMedica,

and eMed, Ms. Mason has served on numerous trade and non-profit boards, including AdvaMed, Partners for Philanthropic Change, Alliance

for Global Good, and the Franciscan Sisters of the Poor Hospitals & Foundation. She currently serves as Chair of the Advisory

and Innovation Council for the UC San Diego Moores Cancer Center. She obtained a B.A. from Indiana University, and completed executive

development programs at Northwestern University, Stanford University, Columbia University, and University of Chicago.

The search for Ms. Mason was conducted by Spencer Stuart, a

worldwide leader in director search and other board advisory services for more than 25 years.

In addition to Ms. Mason, the director nominees Mark B. Logan,

Barry Caldwell, Richard A. Meier, John C. Moore, Charles Slacik, and Kathryn Tunstall were each re-elected to STAAR's Board

of Directors for a term of one year expiring at the 2015 Annual Meeting of Stockholders and until their successors are duly elected

and qualified. As of the record date there were 38,376,146 shares of common stock outstanding and entitled to vote. The voting

result on each proposal was as follows:

About STAAR Surgical

STAAR, which has been dedicated solely to ophthalmic surgery

for over 25 years, designs, develops, manufactures and markets implantable lenses for the eye and delivery systems therefor. All

of these lenses are foldable, which permits the surgeon to insert them through a small incision. STAAR's lens used in refractive

surgery as an alternative to LASIK is called an Implantable Collamer Lens or "ICL." A lens used to replace the natural

lens after cataract surgery is called an intraocular lens or "IOL." More than 425,000 Visian ICLs have been implanted

to date; to learn more about the ICL go to: www.visianinfo.com. STAAR has approximately 335 full time employees and markets lenses

in over 60 countries. Headquartered in Monrovia, CA, it manufactures in the following locations: Nidau, Switzerland; Aliso Viejo,

CA; and Monrovia, CA. For more information, please visit the Company's website at www.staar.com.

All statements in this press release that are not statements

of historical fact are forward-looking statements, including statements about any of the following: any projections of earnings,

revenue, sales, profit margins, cash, effective tax rate or any other financial items; the plans, strategies, and objectives of

management for future operations or prospects for achieving such plans; metrics for 2014; statements regarding new or improved

products, including but not limited to, expectations for success of new or improved products in the U.S. or international markets

or government approval of new or improved products; future economic conditions or size of market opportunities; expected IOL backorder

position; expected costs of Monrovia facility expansion; expected costs and savings from business consolidation plans and the timetable

for those plans; statements of belief, including as to achieving 2014 growth plans or metrics; expected regulatory activities and

approvals, product launches, and any statements of assumptions underlying any of the foregoing. Important additional factors that

could cause actual results to differ materially from those indicated by such forward-looking statements are set forth in the company's

Annual Report on Form 10-K for the year ended January 3, 2014, under the caption "Risk Factors," which is on file with

the Securities and Exchange Commission and available in the "Investor Information" section of the company's website

under the heading "SEC Filings."

These statements are based on expectations and assumptions as

of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ

materially from those described in the forward-looking statements. The risks and uncertainties include the following: our limited

capital resources and limited access to financing; the negative effect of unstable global economic conditions on sales of products,

especially products such as the ICL used in non-reimbursed elective procedures; the challenge of managing our foreign subsidiaries;

backlog or supply delays as we prepare for our manufacturing facility consolidation; the risk of unfavorable changes in currency

exchange rate; the discretion of regulatory agencies to approve or reject new or improved products, or to require additional actions

before approval (including but not limited to determinations by the Ophthalmic Devices Panel of the FDA); unexpected costs or delays

that could reduce or eliminate the expected benefits of our consolidation plans; the risk that research and development efforts

will not be successful or may be delayed in delivering for launch; the purchasing patterns of our distributors carrying inventory

in the market; the willingness of surgeons and patients to adopt a new or improved product and procedure; patterns of Visian ICL

use that have typically limited our penetration of the refractive procedure market, and a general decline in the demand for refractive

surgery particularly in the U.S. and the Asia Pacific region, which STAAR believes has resulted from both concerns about the safety

and effectiveness of laser procedures and current economic conditions. The Visian Toric ICL and the Visian ICL with CentraFLOW

are not yet approved for sale in the United States.